leadf
logo-loader
viewDDD Group

4d pharma reveal positive data from phase II trial of treatment for Irritable Bowel Syndrome

4D pharma plc's (LON:DDD) Alex Stevenson speaks to Proactive London's Katie Pilbeam about the company's latest report which showed positive data for its phase II trial of its live biotherapeutic for irritable bowel syndrome (IBS).

He says the results provide the foundation for continued development of the first drug with the potential to treat both major subtypes of the condition, in both IBS-C and IBS-D subgroups. Stevenson discusses the timeline for Phase III which he says 'would probably take around two years' in several hundred patients.

He also updates investors on his research into oncology and asthma.

Quick facts: DDD Group

Price: - -

AIM:DDD
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Alpha Growth's BlackOak Alpha Growth Fund generates positive returns despite...

Alpha Growth PLC (LON:ALGW) (OTCQB: ALPGF) CEO Gobind Sahney tells Proactive the financial services specialist's BlackOak Alpha Growth Fund produced a 2020 calendar year return of 10.63% and a 13.71% total return since inception in September 2019. Sahney says given the challenges of 2020, its...

3 hours, 30 minutes ago

2 min read